Meet us at the
CBI Clinical Data Disclosure Conference 2020 in Coral Gables (FL) on 22-24 January
Jean-Marc Ferran will be presenting on (1) differences and synergies on Data Sharing requirements across agencies and (2) data utility in anonymised CSRs:
EMA, Health Canada and FDA: Three Agencies Tackle Data Sharing. Synergies and Differences
Abstract: The EMA and then Health Canada have respectively launched separate data transparency policies around sharing of Clinical Study Reports (CSRs). The two regulators are providing additional guidance to help with implementation of their policies and have each formed stakeholders’ groups.
These two stakeholders’ groups include a variety of professionals and representatives across Life Sciences and focus on topics around data anonymisation, risk of re-identification and data utility while Health Canada’s Reference Group also addresses scope and process-related matters.
This presentation will explain the approaches, goals and achievements of these two stakeholders’ groups and reflect on the EMA and Health Canada’s Data Sharing processes and requirements and where they overlap and differ from one another. In addition, the recent initiative and pilots from the FDA will be discussed. The author will also reflect on their experience participating in both stakeholders’ groups and lessons learned that could benefit other Industry committees.
European Medicines Agency Policy 0070: An Exploratory Review of Data Utility in Clinical Study Reports for Academic Research
Abstract: EMA Policy 0070 requires sponsors to demonstrate careful consideration of data utility within anonymised CSRs published within the scope of the Policy, yet the concept of data utility is not clearly defined in the associated anonymisation guidance.
The objective of this work was to review of the objectives, research methodologies and findings of 13 academic research reports using unpublished data from CSRs (prior to EMA Policy 0070) and to hypothesise the potential data utility of CSRs anonymised under the objectives of EMA Policy 0070 for future academic research.
The research purposes ranged from assessment of reporting bias, comparison of methods and results with published data sources, detailed evaluation of harm and adverse events, re-analysis and novel analyses including systematic reviews and meta-analysis.
When & Where
The CBI Clinical Data Disclosure Conference will take place in Coral Gables (FL) on 22-24 January 2020.
Date: 22-24 January 2020
Location: Hyatt Regency Coral Gables
Event Website: CBI Clinical Data Disclosure Conference
CBI Data Disclosure Conference 2020
50 Alhambra Plaza, Coral Gables, FL 33134, USA
GET IN TOUCH
Please get in touch if you would like to meet at this occasion to discuss your projects!
OUR LATEST NEWS
Meet us at the 6th SAS CTDT Forum 2019 in Heidelberg on 26-27 JuneJean-Marc Ferran will be presenting on (1) differences and synergies on Data Sharing requirements across agencies and (2) data utility in anonymised CSRs along with Sarah Nevitt (University of...
Meet us at the PHUSE US CSS 2019 in Silver Spring (MD) on 9-11 June Jean-Marc Ferran will lead the Workshop for the PHUSE Data Transparency Working Group. The following topics will be tackled: Presentations from the FDA and Health Canada on their respective...
Meet us at the PHUSE Copenhagen SDE 2019 on 6. June Jean-Marc Ferran will be presenting on differences and synergies of Data Sharing requirements across agencies: EMA, Health Canada and FDA: Three Agencies Tackle Data Sharing. Synergies and Differences Abstract: The...